Copy to clipboard 
Seikagaku posted 4QFY16 revenue of ¥7.5BB (~US $75.6MM), -6.6% vs. the prior year. (Period ended 3/31/17)
| 1Q17 | 1Q16 | $ Change | % Change | |
| Orthobiologics | $75.6 | $80.9 | -$5.3 | -6.6% |
Quarterly performance highlights:
- Revenue decline attributed to impact of yen appreciation and government-dictated drug price reductions in Japan, despite higher sales volumes in Japan and the U.S.
- Domestically, deliveries of ARTZ to medical institutions increased slightly due to strong marketing and new syringes introduced in 2Q16, though sales to marketing partner decreased due to price reductions
- Ex-Japan, U.S. Gel One sales remain strong, though sales to partner fell slightly due to yen appreciation and decline in local prices, despite an increase in shipment volume
- U.S. SUPARTZ FX sales declined only slightly amid competition from other multi-injection products, and sales to partner were impacted by yen appreciation
- China ARTZ sales to partner decreased on governmental price controls and yen appreciation
- Initiated a Japan Phase III clinical trial in 1Q to study SI-613 hyaluronic acid + NSAID to treat knee OA, partnered with Ono Pharmaceutical for co-development and marketing in the region
Source: Seikagaku Corporation
Seikagaku posted 4QFY16 revenue of ¥7.5BB (~US $75.6MM), -6.6% vs. the prior year. (Period ended 3/31/17)
Q17
1Q16
$ Change
% Change
Orthobiologics
$75.6
$80.9
-$5.3
-6.6%
Quarterly...
Seikagaku posted 4QFY16 revenue of ¥7.5BB (~US $75.6MM), -6.6% vs. the prior year. (Period ended 3/31/17)
| 1Q17 | 1Q16 | $ Change | % Change | |
| Orthobiologics | $75.6 | $80.9 | -$5.3 | -6.6% |
Quarterly performance highlights:
- Revenue decline attributed to impact of yen appreciation and government-dictated drug price reductions in Japan, despite higher sales volumes in Japan and the U.S.
- Domestically, deliveries of ARTZ to medical institutions increased slightly due to strong marketing and new syringes introduced in 2Q16, though sales to marketing partner decreased due to price reductions
- Ex-Japan, U.S. Gel One sales remain strong, though sales to partner fell slightly due to yen appreciation and decline in local prices, despite an increase in shipment volume
- U.S. SUPARTZ FX sales declined only slightly amid competition from other multi-injection products, and sales to partner were impacted by yen appreciation
- China ARTZ sales to partner decreased on governmental price controls and yen appreciation
- Initiated a Japan Phase III clinical trial in 1Q to study SI-613 hyaluronic acid + NSAID to treat knee OA, partnered with Ono Pharmaceutical for co-development and marketing in the region
Source: Seikagaku Corporation
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
